Former Eli Lily exec Alex Azar rumoured to be selected for HHS secretary post

By Catherine Sturman
It has been reported that President Donald Trump is set to appoint former Eli Lily exec Alex Azar to lead the US Department of Health (DoH) and Human Se...

It has been reported that President Donald Trump is set to appoint former Eli Lily exec Alex Azar to lead the US Department of Health (DoH) and Human Services.

Serving as President of Lilly USA LLC from 2012 up to the beginning of 2017 and producing over $8.5bn in revenue, Azar has extensive experience in governmental affairs surrounding the US healthcare sector in both the public and private sector.

Additionally, for two years he has worked as Deputy Secretary of Health and Human Services (HHS), under President Bush, but has also gained in-depth knowledge and international experience surrounding the pharmaceutical and medical field throughout his career.

Related stories

A lawyer by training, Azar is a strong candidate for the role, where he would be responsible for the transformation of the US’ healthcare systems following Trump’s dismantling of Obamacare and ambitions to try and revise the terms surrounding the Affordable Care Act for US citizens. He would take over from previous secretary Tom Price’s resignation.

George W. Bush’s HHS secretary Michael Leavitt informed Bloomberg: “He understands health care, he understands the regulatory process, and he’s skilled in his management. He’d be an able pilot.”

Azar’s knowledge of the pharmaceutical industry will prove vital surrounding the delivery of healthcare for US citizens, the pricing of branded and non-prescription drugs and how the industry is set to transform its service delivery in the face of rising competition and the digitisation of traditional processes.

Image credits

Share
Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma